Dergiler / art / 2015 / Cilt: 30 - Sayı: 2

Macrophage Activation Syndrome: A Potentially Fatal Complication of Kawasaki Disease

Dergi
art
Sayfa
178–180
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The patient responded to dexamethasone in a dose of 10 mg/m2/day.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Kawasaki disease is an acute vasculitis of childhood.
📊
Temel Bulgular & Veri:Macrophage activation syndrome is a rare life threatening complication.
💡
Sonuç & Katkı:The patient responded to dexamethasone in a dose of 10 mg/m2/day.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Kawasaki disease is an acute vasculitis of childhood. Macrophage activation syndrome is a rare life threatening complication. In this article, we report a five-year-six-month old girl patient with Kawasaki disease who developed irritability, hepatosplenomegaly, and pancytopenia after treatment with intravenous immunoglobulins. Patient’s blood test and bone marrow aspiration results suggested macrophage activation syndrome. The patient responded to dexamethasone in a dose of 10 mg/m2/day.

🔖

Bu Makaleye Atıf Yap

BOSE, K., SAHA, S., SAHA, P., MONDAL, P. (2015). Macrophage Activation Syndrome: A Potentially Fatal Complication of Kawasaki Disease. art, Cilt: 30 - Sayı: 2, 178–180. https://ajindex.com/articles/199859

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001;85:421-6
  2. Ziaee V, Moardinejad MH. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Pediatr Rheumatol (Serial Online) 2008;6(1): (62 screens). Available from: http://www.ped-rheum. com/content/6/S1/P62
  3. Mashuku S, Hibi S, Todo S. Hemophagocytic lymphohistiocytosis in infancy and childhood. J Pediatr 1997;130:352-7
  4. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974;54:271-6
  5. Muise A, Tallett SE, Silverman ED. Are Children With Kawasaki Disease and Prolonged Fever at Risk for Macrophage Activation Syndrome? (serial online) Pediatrics 2003;112(495497 screens).Available from: http://pediatrics.aappublications.org/content/112/6/ e495.full.html 6. Wright, DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulse doses of corticosteroids. J Pediatr 1996;128:146-9
  6. Kuzmanova SI. The macrophage activation syndrome: a new entity, a potentially fatal complication of rheumatic disorders. Folia Med (Plovdiv) 2005;47:21-5
  7. Ramanan AV, Schneider R. Macrophage activation syndrome-what’s in a name! J Rheumatol 2003;30:2513-6
  8. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001;85:421-6
  9. Latino GA, Manlhiot C, Yeung RS, Chahal N, McCrindle BW. Macrophage activation syndrome in the acute phase of Kawasaki disease. J Pediatr Hematol Oncol 2010;32:527-31
  10. McClain KL.Treatment and prognosis of hemophagocytic lymphohistiocytosis. Available from: http://www. w3.org/TR/html4/strict. [Accessed 10th July 2014]